We are delighted to be introducing the first new therapeutic option for PBC in nearly 20 years in Europe where this disease is a major reason for liver failure and a leading cause of liver transplant in women, said Lisa Bright, Intercepts President, International. Following approval in the U.S.
Date: Dec 14, 2016
Category: Health
Source: Google
Intercept Pharma's new liver disease drug comes with hefty price tag: $70000 a year
When establishing the price for Ocaliva, we considered several factors including the benefit that Ocaliva offers to people living with PBC, which of course is an orphan disease for which there have been no new treatments in nearly 20 years, said Lisa Bright, the companys chief commercial and corp
In other Intercept Pharmaceuticals news, insider Lisa Bright sold 251 shares of the companys stock in a transaction that occurred on Wednesday, May 25th. The stock was sold at an average price of $137.50, for a total transaction of $34,512.50. Following the completion of the transaction, the inside